ChinaBio® Partnering Forum 2009

23. - 24. Juni 2009

Riverfront Business Hotel
3000 LongDong Avenue
Pudong New Area
Shanghai, China
T: + 86 21 5896 9966
F: + 86 21 5896 9908
www.rfbh.cn

Cross-border M&A and Strategic Alliances in China—Opportunities and Challenges

WilmerHale is a sponsor of the ChinaBio® Partnering Forum 2009.

Moderator: Dr. Rüdiger Herrmann

Speakers:

  • Carl Firth, PhD, MBA, Director, Head of Asia Healthcare, Bank of America Merrill Lynch
  • Michael Heerde, PhD, Director, Strategy and Business Development, Bayer Healthcare China
  • Kewen Jin, PhD, General Manager, Charles River Greater China
  • Victor Shi, PhD, Asia President, QIAGEN

China's drug market is growing at an enormous speed and has become an essential market for all big pharma and biotech players. In addition to increasing direct investment into China, overseas players have different initiatives and plans in forming strategic alliances with local companies in terms of R&D, manufacturing, commercialization as well as service. Influenced by the Chinese government incentives and the tremendously growing talent pool, Chinese life sciences companies are getting competitive on an international level. As a consequence, more cross-border M&As will also take place in this industry. Our seasoned speakers in this panel will address in detail what are the opportunities and challenges accompanying such exciting transactions.

For more information please click here.